Data from the RESMAIN study of Kinselby (resminostat) have been presented at the 5th World Congress of Cutaneous Lymphomas (5WCCL), at the City of Hope, Pasaden 11 April 2024
Los Angeles-based TORL BioTherapeutics, a biotech focused on discovering and developing antibody-based immunotherapies, has closed an oversubscribed $158 millio 10 April 2024
A private share placement is set to land Massachusetts, USA-based Acrivon Therapeutics with an additional $130 million to fund its oncology research. 10 April 2024
Antibody drug conjugates (ADCs) are currently in vogue with investors and big pharma, as a rapidly emerging class of therapeutic agents that combine the target 10 April 2024
Swiss drugmaker Novartis has revealed fresh plans to slim down its workforce, with a further 680 US and Swiss jobs to be cut from its development organizational 10 April 2024
Increasing demand for targeted therapies is driving demand in the antibody discovery market, finds industry analyst Future Market Insights. 8 April 2024
British life sciences investor Medicxi is betting $40 million on a Shanghai-based biotech, D3 Bio, working in the areas of oncology and immunology. 8 April 2024
A trial failure for eFFECTOR Therapeutics has prompted the Californian firm to drop development of its lead candidate, tomivosertib, in lung cancer. 5 April 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.